Selectins and their ligands as potential immunotherapeutic targets in neurological diseases

Immunotherapy

Volumn 5, Issue 11, 2013, Pages 1207-1220

  Angiari, Stefano ^a   Constantin, Gabriela ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

disease therapy; inflammation; leukocyte trafficking; rolling; selectin

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ASELIZUMAB; BIMOSIAMOSE; CDP 850; CY 1503; CYLEXIN; EFALIZUMAB; LIGAND; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY SELG1; MONOCLONAL ANTIBODY SELK2; NATALIZUMAB; PSI 697; RIVIPANSEL; SELECTIN; SIALYL LEWIS X ANTIGEN; UNCLASSIFIED DRUG;

ALLERGY; BRAIN ISCHEMIA; CELL INTERACTION; CROHN DISEASE; ENDOTHELIUM; EPILEPSY; HUMAN; IMMUNOTHERAPY; LEUKOCYTE; LUNG INJURY; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PSORIASIS; RESPIRATORY TRACT INFLAMMATION; REVIEW; SCLERITIS; SICKLE CELL ANEMIA; TRAUMATIC BRAIN INJURY; UNSPECIFIED SIDE EFFECT;

ANIMALS; BRAIN DISEASES; CELL COMMUNICATION; CELL MOVEMENT; HUMANS; IMMUNOTHERAPY; LEUKOCYTES; LIGANDS; MULTIPLE SCLEROSIS; SELECTINS;

EID: 84887247750     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.122     Document Type: Review

References (138)

1. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of infammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol. 7, 678-689 (2007). (Pubitemid 47327397)
2. Ley K, Kansas GS. Selectins in T-cell recruitment to non-lymphoid tissues and sites of infammation. Nat. Rev. Immunol. 4, 325-335 (2004). (Pubitemid 38649275)
3. Zarbock A, Ley K, McEver RP, Hidalgo A. Leukocyte ligands for endothelial selectins: specialized glycoconjugates that mediate rolling and signaling under fow. Blood 118, 6743-6751 (2011).
4. Lee WY, Kubes P. Leukocyte adhesion in the liver: distinct adhesion paradigm from other organs. J. Hepatol. 48, 504-512 (2008).
5. Mizgerd JP, Meek BB, Kutkoski GJ, Bullard DC, Beaudet AL, Doerschuk CM. Selectins and neutrophil traffc: margination and Streptococcus pneumoniae-induced emigration in murine lungs. J. Exp. Med. 184, 639-645 (1996). (Pubitemid 26324117)
6. Ley K. The role of selectins in infammation and disease. Trends. Mol. Med. 9, 263-268 (2003).
7. Romo GM, Dong JF, Schade AJ et al. The glycoprotein Ib-IX-V complex is a platelet counterreceptor for P-selectin. J. Exp. Med. 190, 803-814 (1999).
8. Aigner S, Sthoeger ZM, Fogel Met al. CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. Blood 89, 3385-3395 (1997). (Pubitemid 27229826)
9. Hidalgo A, Peired AJ, Wild MK, Vestweber D, Frenette PS. Complete identifcation of E-selectin ligands on neutrophils reveals distinct functions of PSGL-1, ESL-1, and CD. Immunity 26, 477-489 (2007). (Pubitemid 46603003)
10. Rossi FM, Corbel SY, Merzaban JS et al. Recruitment of adult thymic progenitors is regulated by P-selectin and its ligand PSGL-1. Nat. Immunol. 6, 626-634 (2005). (Pubitemid 41710734)
11. Ransohoff RM, Engelhardt B. The anatomical and cellular basis of immune surveillance in the central nervous system. Nat. Rev. Immunol. 12, 623-635 (2012).
12. + T (RM) cells providing global skin immunity Nature 483, 227-231 (2012).
13. Furlan R, Cuomo C, Martino G. Animal models of multiple sclerosis. Methods. Mol. Biol. 549, 157-173 (2009).
14. Rossi B, Angiari S, Zenaro E, Budui SL, Constantin G. Vascular infammation in central nervous system diseases: adhesion receptors controlling leukocyte-endothelial interactions. J. Leukoc. Biol. 89, 539-556 (2011).
15. Piccio L, Rossi B, Scarpini E et al. Molecular mechanisms involved in lymphocyte recruitment in infamed brain microvessels: critical roles for P-selectin glycoprotein ligand-1 and heterotrimeric G(i)-linked receptors. J. Immunol. 168, 1940-1949 (2002). (Pubitemid 34135797)
16. Vajkoczy P, Laschinger M, Engelhardt B. Alpha 4-integrin-VCAM-1 binding mediates G protein-independent capture of encephalitogenic T cell blasts to CNS white matter microvessels. J. Clin. Invest. 108, 557-565 (2001). (Pubitemid 32777735)
17. Sundd P, Gutierrez E, Koltsova EK et al. 'Slings' enable neutrophil rolling at high shear. Nature 488, 399-403 (2012).
18. Stüve O, Gold R, Chan A, Mix E, Zettl U, Kieseier BC. alpha 4-Integrin antagonism with natalizumab: effects and adverse effects. J. Neurol. 255, 58-65 (2008).
19. Engelhardt B, Vestweber D, Hallmann R, Schulz M. E-and P-selectin are not involved in the recruitment of infammatory cells across the blood-brain barrier in experimental autoimmune encephalomyelitis. Blood 90, 4459-4472 (1997). (Pubitemid 27508451)
20. Kerfoot SM, Kubes P. Overlapping roles of P-selectin and alpha 4 integrin to recruit leukocytes to the central nervous system in experimental autoimmune encephalomyelitis. J. Immunol. 169, 1000-1006 (2002). (Pubitemid 34753459)
21. Zhao J, Gao Y, Cheng C, Yan M, Wang J. Upregulation of b-1, 4-galactosyltransferase I in rat spinal cord with experimental autoimmune encephalomyelitis. J. Mol. Neurosci. 49, 437-445 (2013).
22. Piccio L, Rossi B, Colantonio L et al. Effcient recruitment of lymphocytes in infamed brain venules requires expression of cutaneous lymphocyte antigen and fucosyltransferase-VII. J. Immunol. 174, 5805-5813 (2005). (Pubitemid 40593225)
23. Kerfoot SM, Norman MU, Lapointe BM, Bonder CS, Zbytnuik L, Kubes P. Reevaluation of P-selectin and alpha 4 integrin as targets for the treatment of experimental autoimmune encephalomyelitis. J. Immunol. 176, 6225-6234 (2006).
24. Döring A, Wild M, Vestweber D, Deutsch U, Engelhardt B. E-and P-selectin are not required for the development of experimental autoimmune encephalomyelitis in C57BL/6 and SJL mice. J. Immunol. 179, 8470-8479 (2007).
25. Washington R, Burton J, Todd RF 3rd, Newman W, Dragovic L, Dore-Duffy P. Expression of immunologically relevant endothelial cell activation antigens on isolated central nervous system microvessels from patients with multiple sclerosis. Ann. Neurol. 35, 89-97 (1994). (Pubitemid 24027611)
26. Lee SJ, Benveniste EN. Adhesion molecule expression and regulation on cells of the central nervous system. J. Neuroimmunol. 98, 77-88 (1999). (Pubitemid 29317533)
27. Rieckmann P, Martin S, Weichselbraun I et al. Serial ana lysis of circulating adhesion molecules and TNF receptor in serum from patients with multiple sclerosis: cICAM-1 is an indicator for relapse. Neurology 44, 2367-2372 (1994). (Pubitemid 24382739)
28. Dore-Duffy P, Newman W, Balabanov R et al. Circulating, soluble adhesion proteins in cerebrospinal fuid and serum of patients with multiple sclerosis: correlation with clinical activity. Ann. Neurol. 37, 55-62 (1995).
29. McDonnell GV, McMillan SA, Douglas JP, Droogan AG, Hawkins SA. Raised CSF levels of soluble adhesion molecules across the clinical spectrum of multiple sclerosis. J. Neuroimmunol. 85, 186-192 (1998). (Pubitemid 28313503)
30. Hartung HP, Reiners K, Archelos JJ et al. Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging. Ann. Neurol. 38, 186-193 (1995).
31. Kuenz B, Lutterotti A, Khalil M et al. Plasma levels of soluble adhesion molecules sPECAM-1, sP-selectin and sE-selectin are associated with relapsing-remitting disease course of multiple sclerosis. J. Neuroimmunol. 167, 143-149 (2005). (Pubitemid 41242296)
32. Sellner J, Koczi W, Harrer A et al. Glatiramer acetate attenuates the pro-migratory profle of adhesion molecules on various immune cell subsets in multiple sclerosis. Clin. Exp. Immunol. 173, 381-389 (2013).
33. Sheremata WA, Jy W, Horstman LL, Ahn YS, Alexander JS, Minagar A. Evidence of platelet activation in multiple sclerosis. J. Neuroinfam. 5, 27 (2008).
34. Archelos JJ, Jung S, Rinner W, Lassmann H, Miyasaka M, Hartung HP. Role of the leukocyte-adhesion molecule L-selectin in experimental autoimmune encephalomyelitis. J. Neurol. Sci. 159, 127-134 (1998). (Pubitemid 28384517)
35. Brocke S, Piercy C, Steinman L, Weissman IL, Veromaa T. Antibodies to CD44 and integrin alpha 4, but not L-selectin, prevent central nervous system infammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment. Proc. Natl Acad. Sci. USA 96, 6896-6901 (1999). (Pubitemid 29274981)
36. Grewal IS, Foellmer HG, Grewal KD et al. CD62L is required on effector cells for local interactions in the CNS to cause myelin damage in experimental allergic encephalomyelitis. Immunity 14, 291-302 (2001). (Pubitemid 32289293)
37. Li O, Liu JQ, Zhang H, Zheng P, Liu Y, Bai XF. CD62L is required for the priming of encephalitogenic T cells but does not play a major role in the effector phase of experimental autoimmune encephalomyelitis. Scand. J. Immunol. 64, 117-124 (2006). (Pubitemid 44034315)
38. Uboldi C, Döring A, Alt C, Estess P, Siegelman M, Engelhardt B. L-selectin-defcient SJL and C57BL/6 mice are not resistant to experimental autoimmune encephalomyelitis. Eur. J. Immunol. 38, 2156-2167 (2008).
39. Durán I, Martínez-Cáceres EM, Río J, Barberà N, Marzo ME, Montalban X. Immunological profle of patients with primary progressive multiple sclerosis. Expression of adhesion molecules. Brain 122, 2297-2307 (1999).
40. Deshpande P, King IL, Segal BM. IL-12 driven upregulation of P-selectin ligand on myelin-specifc T cells is a critical step in an animal model of autoimmune demyelination. J. Neuroimmunol. 173, 35-44 (2006).
41. Engelhardt B, Kempe B, Merfeld-Clauss S et al. P-selectin glycoprotein ligand 1 is not required for the development of experimental autoimmune encephalomyelitis in SJL and C57BL/6 mice. J. Immunol. 175, 1267-1275 (2005). (Pubitemid 41095016)
42. +T cells from patients with acute multiple sclerosis display selective increase of adhesiveness in brain venules: a critical role for P-selectin glycoprotein ligand. Blood 101, 4775-4782 (2003). (Pubitemid 36857734)
43. Bahbouhi B, Berthelot L, Pettré S et al. Peripheral blood CD4+ T lymphocytes from multiple sclerosis patients are characterized by higher PSGL-1 expression and transmigration capacity across a human blood-brain barrier-derived endothelial cell line. J. Leukoc. Biol. 86, 1049-1063 (2009).
44. Steffen BJ, Breier G, Butcher EC, Schulz M, Engelhardt B. ICAM-1, VCAM-1, and MAdCAM-1 are expressed on choroid plexus epithelium but not endothelium and mediate binding of lymphocytes in vitro. Am. J. Pathol. 148, 1819-1838 (1996).
45. Kanwar JR, Harrison JE, Wang D et al. Beta 7 integrins contribute to demyelinating disease of the central nervous system. J. Neuroimmunol. 103, 146-152 (2000). (Pubitemid 30079726)
46. Döring A, Pfeiffer F, Meier Met al. TET inducible expression of the a4b7-integrin ligand MAdCAM-1 on the blood-brain barrier does not infuence the immunopathogenesis of experimental autoimmune encephalomyelitis. Eur. J. Immunol. 41, 813-821 (2011).
47. Kanwar JR, Kanwar RK, Wang D, Krissansen GW. Prevention of a chronic progressive form of experimental autoimmune encephalomyelitis by an antibody against mucosal addressin cell adhesion molecule-1, given early in the course of disease progression. Immunol. Cell. Biol. 78, 641-645 (2000).
48. Kanwar JR, Kanwar RK, Krissansen GW. Simultaneous neuroprotection and blockade of infammation reverses autoimmune encephalomyelitis. Brain 127, 1313-1331 (2004). (Pubitemid 38745510)
49. Bai XF, Li O, Zhou Qet al. CD24 controls expansion and persistence of autoreactive T cells in the central nervous system during experimental autoimmune encephalomyelitis. J. Exp. Med. 200, 447-458(2004). (Pubitemid 39121902)
50. Langer HF, Choi EY, Zhou H et al. Platelets contribute to the pathogenesis of experimental autoimmune encephalomyelitis. Circ. Res. 110, 1202-1210 (2012).
51. Jeon SB, Yoon HJ, Park SH, Kim IH, Park EJ. Sulfatide, a major lipid component of myelin sheath, activates infammatory responses as an endogenous stimulator in brain-resident immune cells. J. Immunol. 181, 8077-8087 (2008).
52. Hurwitz AA, Lyman WD, Guida MP, Calderon TM, Berman JW. Tumor necrosis factor alpha induces adhesion molecule expression on human fetal astrocytes. J. Exp. Med. 176, 1631-1636 (1992).
53. Shen A, Chen J, Qian J et al. Elevated beta 1, 4-galactosyltransferase-I induced by the intraspinal injection of lipopolysaccharide. Glycoconj. J. 26, 19-31 (2009).
54. Kipp M, Norkute A, Johann S et al. Brain-region-specifc astroglial responses in vitro after LPS exposure. J. Mol. Neurosci. 35, 235-243 (2008).
55. Galimberti D, Fenoglio C, Clerici R et al. E-selectin A561C and G98T polymorphisms infuence susceptibility and course of multiple sclerosis. J. Neuroimmunol. 165, 201-205 (2005). (Pubitemid 40984639)
56. Fenoglio C, Scalabrini D, Piccio L et al. Candidate gene ana lysis of selectin cluster in patients with multiple sclerosis. J. Neurol. 256, 832-833 (2009).
57. Zhou Q, Rammohan K, Lin S et al. CD24 is a genetic modifer for risk and progression of multiple sclerosis. Proc. Natl Acad. Sci. USA 100, 15041-15046 (2003). (Pubitemid 37518013)
58. Otaegui D, Sáenz A, Camaño P et al. CD24 V/V is an allele associated with the risk of developing multiple sclerosis in the Spanish population. Mult. Scler. 12, 511-514 (2006). (Pubitemid 44132594)
59. Ronaghi M, Vallian S, Etemadifar M. CD24 gene polymorphism is associated with the disease progression and susceptibility to multiple sclerosis in the Iranian population. Psychiatry Res. 170, 271-272 (2009).
60. Kollaee A, Ghaffarpor M, Pourmahmoudian H, Shahbazi M, Zamani M. Investigation of CD24 and its expression in Iranian relapsing-remitting multiple sclerosis. Int. J. Neurosci. 121, 684-690 (2011).
61. Wang L, Lin S, Rammohan KW et al. A dinucleotide deletion in CD24 confers protection against autoimmune diseases. PLoS Genet. 3, e49 (2007).
62. González SJ, Rojas JI, Redal MA et al. CD24 as a genetic modifer of disease progression in multiple sclerosis in Argentinean patients. J. Neurol. Sci. 307, 18-21 (2011).
63. Wang L, Liu R, Li D et al. A hypermorphic SP1-binding CD24 variant associates with risk and progression of multiple sclerosis. Am. J. Transl. Res. 4, 347-356 (2012).
64. Scalabrini D, Galimberti D, Fenoglio C et al. P-selectin glycoprotein ligand-1 variable number of tandem repeats (VNTR) polymorphism in patients with multiple sclerosis. Neurosci. Lett. 388, 149-152 (2005). (Pubitemid 41208210)
65. Yilmaz G, Granger DN. Leukocyte recruitment and ischemic brain injury. Neuromolecular Med. 12, 193-204 (2010).
66. Chamorro Á, Meisel A, Planas AM, Urra X, van de Beek D, Veltkamp R. The immunology of acute stroke. Nat. Rev. Neurol. 8, 401-410 (2012).
67. Okada Y, Copeland BR, Mori E, Tung MM, Thomas WS, del Zoppo GJ. P-selectin and intercellular adhesion molecule-1 expression after focal brain ischemia and reperfusion. Stroke 25, 202-211 (1994).
68. Haring HP, Berg EL, Tsurushita N, Tagaya M, del Zoppo GJ. E-selectin appears in nonischemic tissue during experimental focal cerebral ischemia. Stroke 27, 1386-1391 (1996).
69. Zhang RL, Chopp M, Zhang ZG et al. E-selectin in focal cerebral ischemia and reperfusion in the rat. J. Cereb. Blood Flow Metab. 16, 1126-1136 (1996). (Pubitemid 26365363)
70. Zhang R, Chopp M, Zhang Z, Jiang N, Powers C. The expression of P-and E-selectins in three models of middle cerebral artery occlusion. Brain Res. 785, 207-214 (1998). (Pubitemid 28179383)
71. Ishikawa M, Cooper D, Arumugam TV, Zhang JH, Nanda A, Granger DN. Platelet-leukocyte-endothelial cell interactions after middle cerebral artery occlusion and reperfusion. J. Cereb. Blood Flow Metab. 24, 907-915 (2004). (Pubitemid 39045408)
72. Lehmberg J, Beck J, Baethmann A, Uhl E. Effect of P-selectin inhibition on leukocyte-endothelium interaction and survival after global cerebral ischemia. J. Neurol. 253, 357-363 (2006).
73. Ishikawa M, Cooper D, Russell J et al. Molecular determinants of the prothrombogenic and infammatory phenotype assumed by the postischemic cerebral microcirculation. Stroke 34, 1777-1782 (2003). (Pubitemid 36842645)
74. Love S, Barber R. Expression of P-selectin and intercellular adhesion molecule-1 in human brain after focal infarction or cardiac arrest. Neuropathol. Appl. Neurobiol. 27, 465-473 (2001). (Pubitemid 34264262)
75. McCabe DJ, Harrison P, Mackie IJ et al. Platelet degranulation and monocyte-platelet complex formation are increased in the acute and convalescent phases after ischaemic stroke or transient ischaemic attack. Br. J. Haematol. 125, 777-787 (2004). (Pubitemid 38813605)
76. Nadar SK, Lip GY, Blann AD. Platelet morphology, soluble P selectin and platelet P-selectin in acute ischaemic stroke. The West Birmingham Stroke Project. Thromb. Haemost. 92, 1342-1348 (2004). (Pubitemid 39642546)
77. Zeller JA, Lenz A, Eschenfelder CC, Zunker P, Deuschl G. Platelet-leukocyte interaction and platelet activation in acute stroke with and without preceding infection. Arterioscler. Thromb. Vasc. Biol. 25, 1519-1523 (2005). (Pubitemid 40923378)
78. Frijns CJ, Kappelle LJ, van Gijn J, Nieuwenhuis HK, Sixma JJ, Fijnheer R. Soluble adhesion molecules refect endothelial cell activation in ischemic stroke and in carotid atherosclerosis. Stroke 28, 2214-2218 (1997). (Pubitemid 27497925)
79. Fassbender K, Mössner R, Motsch L, Kischka U, Grau A, Hennerici M. Circulating selectin-and immunoglobulin-type adhesion molecules in acute ischemic stroke. Stroke 26, 1361-1364 (1995).
80. Mocco J, Choudhri T, Huang J et al. HuEP5C7 as a humanized monoclonal anti-E/P-selectin neurovascular protective strategy in a blinded placebo-controlled trial of nonhuman primate stroke. Circ. Res. 91, 907-914 (2002). (Pubitemid 35373590)
81. Goussev AV, Zhang Z, Anderson DC, Chopp M. P-selectin antibody reduces hemorrhage and infarct volume resulting from MCA occlusion in the rat. J. Neurol. Sci. 161, 16-22 (1998). (Pubitemid 28559178)
82. Huang J, Choudhri TF, Winfree CJ et al. Postischemic cerebrovascular E-selectin expression mediates tissue injury in murine stroke. Stroke 31, 3047-3053 (2000).
83. Connolly ES Jr, Winfree CJ, Prestigiacomo CJ et al. Exacerbation of cerebral injury in mice that express the P-selectin gene: identifcation of P-selectin blockade as a new target for the treatment of stroke. Circ. Res. 81, 304-310 (1997). (Pubitemid 27362516)
84. Jin AY, Tuor UI, Rushforth D et al. Reduced blood brain barrier breakdown in P-selectin defcient mice following transient ischemic stroke: a future therapeutic target for treatment of stroke. BMC Neurosci. 11, 12 (2010).
85. Ma XJ, Cheng J W, Zhang J et al. E-selectin defciency attenuates brain ischemia in mice. CNS Neurosci. Ther. 18, 903-908 (2012).
86. Uhm CS, Kim KB, Lim JH et al. Effective treatment with fucoidin for perinatal hypoxic-ischemic encephalopathy in rats. Neurosci. Lett. 353, 21-24 (2003). (Pubitemid 37464610)
87. Morikawa E, Zhang SM, Seko Y, Toyoda T, Kirino T. Treatment of focal cerebral ischemia with synthetic oligopeptide corresponding to lectin domain of selectin. Stroke 27, 951-955 (1996).
88. Takeda H, Spatz M, Ruetzler C, McCarron R, Becker K, Hallenbeck J. Induction of mucosal tolerance to E-selectin prevents ischemic and hemorrhagic stroke in spontaneously hypertensive genetically stroke-prone rats. Stroke 33, 2156-2163 (2002). (Pubitemid 35014621)
89. Chen Y, Ruetzler C, Pandipati S et al. Mucosal tolerance to E-selectin provides cell-mediated protection against ischemic brain injury. Proc. Natl Acad. Sci. USA 100, 15107-15112 (2003). (Pubitemid 37518024)
90. Ishibashi S, Maric D, Mou Y, Ohtani R, Ruetzler C, Hallenbeck JM. Mucosal tolerance to E-selectin promotes the survival of newly generated neuroblasts via regulatory T-cell induction after stroke in spontaneously hypertensive rats. J. Cereb. Blood Flow Metab. 29, 606-620 (2009).
91. Wei YS, Lan Y, Meng LQ, Nong LG. The association of L-selectin polymorphisms with L-selectin serum levels and risk of ischemic stroke. J. Thromb. Thrombolysis 32, 110-115 (2011).
92. Tsai NW, Chang WN, Shaw CF et al. The value of leukocyte adhesion molecules in patients after ischemic stroke. J. Neurol. 256, 1296-1302 (2009).
93. Lozano ML, González-Conejero R, Corral J et al. Polymorphisms of P-selectin glycoprotein ligand-1 are associated with neutrophil-platelet adhesion and with ischaemic cerebrovascular disease. Br. J. Haematol. 115, 969-976 (2001). (Pubitemid 34042918)
94. Wang X, Xu L, Wang H, Zhan Y, Puré E, Feuerstein GZ. CD44 defciency in mice protects brain from cerebral ischemia injury J. Neurochem. 83, 1172-1179 (2002). (Pubitemid 35397126)
95. De Meyer SF, Schwarz T, Deckmyn H et al. Binding of von Willebrand factor to collagen and glycoprotein Ibalpha, but not to glycoprotein IIb/IIIa, contributes to ischemic stroke in mice-brief report. Arterioscler. Thromb. Vasc. Biol. 30, 1949-1951 (2010).
96. Padilla A, Moake JL, Bernardo A et al. P-selectin anchors newly released ultralarge von Willebrand factor multimers to the endothelial cell surface. Blood 103, 2150-2156 (2004). (Pubitemid 38326232)
97. Pendu R, Terraube V, Christophe OD et al. P-selectin glycoprotein ligand 1 and beta 2-integrins cooperate in the adhesion of leukocytes to von Willebrand factor. Blood 108, 3746-3752 (2006). (Pubitemid 44864554)
98. Zee RY, Cook NR, Cheng S et al. Polymorphism in the P-selectin and interleukin-4 genes as determinants of stroke: a population-based, prospective genetic analysis. Hum. Mol. Genet. 13, 389-396 (2004). (Pubitemid 38239790)
99. Haidari M, Hajilooi M, Rafei AR, Rezaii AA, Hoseinipanah SM. E-selectin genetic variation as a susceptibility factor for ischemic stroke. Cerebrovasc. Dis. 28, 26-32 (2009).
100. Zhao DX, Feng J, Cong SY, Zhang W Association of E-selectin gene polymorphisms with ischemic stroke in a Chinese Han population. J. Neurosci. Res. 90, 1782-1787 (2012).
101. Volcik KA, Ballantyne CM, Coresh J, Folsom AR, Boerwinkle E. Specifc P-selectin and P-selectin glycoprotein ligand-1 genotypes/haplotypes are associated with risk of incident CHD and ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis 195, e76-e82 (2007). (Pubitemid 47561962)
102. Helmy A, De Simoni MG, Guilfoyle MR, Carpenter KL, Hutchinson PJ. Cytokines and innate infammation in the pathogenesis of human traumatic brain injury. Prog. Neurobiol. 95, 352-372 (2011).
103. Carlos TM, Clark RS, Franicola-Higgins D, Schiding JK, Kochanek PM. Expression of endothelial adhesion molecules and recruitment of neutrophils after traumatic brain injury in rats. J. Leukoc. Biol. 61, 279-285 (197).
104. Williams AJ, Wei HH, Dave JR, Tortella FC. Acute and delayed neuroinfammatory response following experimental penetrating ballistic brain injury in the rat. J. Neuroinfammation 4, 17 (2007).
105. Israelsson C, Bengtsson H, Kylberg Aet al. Distinct cellular patterns of upregulated chemokine expression supporting a prominent infammatory role in traumatic brain injury. J. Neurotrauma 25, 959-974 (2008).
106. Whalen MJ, Carlos TM, Kochanek PMet al. Neutrophils do not mediate blood-brain barrier permeability early after controlled cortical impact in rats. J. Neurotrauma 16, 583-594 (1999). (Pubitemid 29350517)
107. Fabene PF, Navarro Mora G, Martinello M et al. A role for leukocyte-endothelial adhesion mechanisms in epilepsy. Nat. Med. 14, 1377-1383 (2008).
108. Whalen MJ, Carlos TM, Kochanek PMet al. Soluble adhesion molecules in CSF are increased in children with severe head injury. J. Neurotrauma 15, 777-787 (1998). (Pubitemid 28487992)
109. Mussack T, Biberthaler P, Gippner-Steppert C et al. Early cellular brain damage and systemic infammatory response after cardiopulmonary resuscitation or isolated severe head trauma: a comparative pilot study on common pathomechanisms. Resuscitation 49, 193-199 (2001). (Pubitemid 32520933)
110. McKeating EG, Andrews PJ, Mascia L. The relationship of soluble adhesion molecule concentrations in systemic and jugular venous serum to injury severity and outcome after traumatic brain injury. Anesth. Analg. 86, 759-765 (1998). (Pubitemid 28177728)
111. Briassoulis G, Papassotiriou I, Mavrikiou M, Lazaropoulou C, Margeli A. Longitudinal course and clinical signifcance of TGF-beta 1, sL-and sE-Selectins and sICAM-1 levels during severe acute stress in children. Clin. Biochem. 40, 299-304 (2007).
112. Grady MS, Cody RF Jr, Maris DO et al. P-selectin blockade following fuid-percussion injury: behavioral and immunochemical sequelae. J. Neurotrauma 16, 13-25 (1999). (Pubitemid 29061893)
113. Whalen MJ, Carlos TM, Dixon CE et al. Reduced brain edema after traumatic brain injury in mice defcient in P-selectin and intercellular adhesion molecule. J. Leukoc.Biol. 67, 160-168 (2000).
114. Fabene PF, Laudanna C, Constantin G. Leukocyte traffcking mechanisms in epilepsy. Mol. Immunol. 55, 100-104 (2013).
115. Williams AJ, Berti R, Yao C et al. Central neuro-infammatory gene response following soman exposure in the rat. Neurosci. Lett. 349, 147-150 (2003). (Pubitemid 37297799)
116. Librizzi L, Regondi MC, Pastori C, Frigerio S, Frassoni C, de Curtis M. Expression of adhesion factors induced by epileptiform activity in the endothelium of the isolated guinea pig brain in vitro. Epilepsia 48, 743-751 (2007). (Pubitemid 46587609)
117. Wakamoto H, Ohta M, Nakano N. Hypercytokinemia in hemiconvulsions- hemiplegia syndrome associated with dual infection with varicella zoster and Epstein-Barr viruses. Neuropediatrics 33, 262-265 (2002). (Pubitemid 36134201)
118. Boer K, Crino PB, Gorter JA et al. Gene expression ana lysis of tuberous sclerosis complex cortical tubers reveals increased expression of adhesion and infammatory factors. Brain Pathol. 20, 704-719 (2010).
119. Masuda Y. Lewis-x, a sugar chain structure, suppresses the epileptic seizure in El mouse. SeishinShinkeigakuZasshi 97, 422-429 (1995).
120. Luster AD, Alon R, von Andrian UH. Immune cell migration in infammation: present and future therapeutic targets. Nat. Immunol. 6, 1182-1190 (2005). (Pubitemid 43045626)
121. Rossi B, Constantin G. Anti-selectin therapy for the treatment of infammatory diseases. Infamm. Allergy Drug Targets 7, 85-93 (2008).
122. Ernst B, Magnani JL. From carbohydrate leads to glycomimetic drugs. Nat. Rev. Drug Discov. 8, 661-677 (2009).
123. Bhushan M, Bleiker TO, Ballsdon AE et al. Anti-E-selectin is ineffective in the treatment of psoriasis: a randomized trial. Br. J. Dermatol. 146, 824-831 (2002). (Pubitemid 34539192)
124. Seekamp A, van Griensven M, Dhondt E et al. The effect of anti-L-selectin (aselizumab) in multiple traumatized patients-results of a Phase II clinical trial. Crit. Care Med. 32, 2021-2028 (2004). (Pubitemid 39372535)
125. Mertens P, Maes A, Nuyts J et al. Recombinant P-selectin glycoprotein ligand-immunoglobulin, a P-selectin antagonist, as an adjunct to thrombolysis in acute myocardial infarction. The P-Selectin Antagonist Limiting Myonecrosis (PSALM) trial. Am. Heart J. 152, 125.e1-125.e8 (2006).
126. Gaber AO, Mulgaonkar S, Kahan BD et al. YSPSL (rPSGL-Ig) for improvement of early renal allograft function: a double-blind, placebo-controlled, multi-center Phase IIa study. Clin. Transplant. 25, 523-533 (2011).
127. Busuttil RW, Lipshutz GS, Kupiec-Weglinski JW et al. rPSGL-Ig for improvement of early liver allograft function: a double-blind, placebo-controlled, single-center Phase II study. Am. J. Transplant. 11, 786-797 (2011).
128. Kerr KM, Auger WR, Marsh JJ et al. The use of cylexin (CY-1503) in prevention of reperfusion lung injury in patients undergoing pulmonary thromboendarterectomy. Am. J. Respir. Crit. Care Med. 162, 14-20 (2000). (Pubitemid 30469791)
129. Beeh KM, Beier J, Meyer M, Buhl R, Zahlten R, Wolff G. Bimosiamose, an inhaled small-molecule pan-selectin antagonist, attenuates late asthmatic reactions following allergen challenge in mild asthmatics: a randomized, double-blind, placebo-controlled clinical cross-over-trial. Pulm. Pharmacol. Ther. 19, 233-241 (2006).
130. Kirsten A, Watz H, Kretschmar G et al. Effcacy of the pan-selectin antagonist Bimosiamose on ozone-induced airway infammation in healthy subjects-a double blind, randomized, placebo-controlled, cross-over clinical trial. Pulm. Pharmacol. Ther. 24, 555-558 (2011).
131. Watz H, Bock D, Meyer M et al. Inhaled pan-selectin antagonist Bimosiamose attenuates airway infammation in COPD. Pulm. Pharmacol. Ther. 26, 265-270 (2013).
132. Friedrich M, Bock D, Philipp S et al. Pan-selectin antagonism improves psoriasis manifestation in mice and man. Arch. Dermatol. Res. 297, 345-351 (2006). (Pubitemid 43144265)
133. Chang J, Patton JT, Sarkar A, Ernst B, Magnani JL, Frenette PS. GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice. Blood 116, 1779-1786 (2010).
134. Baumann K, Kowalczyk D, Gutjahr T et al. Sulfated and non-sulfated glycopeptide recognition domains of P-selectin glycoprotein ligand 1 and their binding to P-and E-selectin. Angew. Chem. Int. Ed. Engl. 48, 3174-3178 (2009).
135. Griffth J W, Luster AD. Targeting cells in motion: Migrating toward improved therapies. Eur. J. Immunol. 43, 1430-1435 (2013).
136. Weger W. Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br. J. Pharmacol. 160, 810-820 (2010).
137. Sotgiu S, Murrighile MR, Constantin G. Treatment of refractory epilepsy with natalizumab in a patient with multiple sclerosis. Case report. BMC Neurol. 10, 84 (2010).
138. Schwab N, Ulzheimer JC, Fox RJet al. Fatal PML associated with efalizumab therapy: insights into integrin aLb2 in JC virus control. Neurology 78, 458-467 (2012).